Plain-English translation of NCT07623941 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study is tracking men with early prostate cancer who choose to receive focal therapy — a newer approach that uses either high-intensity focused ultrasound (HIFU) or irreversible electroporation (IRE) to destroy only the cancer area, not the entire prostate. The study evaluates how well these treatments work and how they affect quality of life and sexual and urinary function.
Traditional prostate cancer treatment often means removing the entire prostate or getting whole-gland radiation, which can cause side effects like erectile dysfunction and urinary problems. This study exists to understand whether treating only the cancerous area with these newer technologies can effectively fight cancer while preserving more normal function.
You likely qualify if…
You likely don't qualify if…
You would receive either focused ultrasound or electrical energy treatment to your prostate cancer area in a hospital setting. After treatment, you would return for follow-up visits to monitor your cancer control, sexual function, urinary health, and quality of life. Some patients may have follow-up biopsies to confirm the cancer was successfully treated. The study collects information about how well the treatment works and how it affects your daily life over time.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Sponsor
Columbia University
Enrollment target
~1,000 participants
Started
January 2026
Primary completion
December 2035
Age range
40 Years – 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in June 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.